Biomarin Pharmaceutical Inc BMRN:NASDAQ

Last Price$73.74NASDAQ Previous Close - Last Trade as of 4:00PM ET 10/22/21
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$73.00 (3)
Ask (Size)$75.50 (1)
Day Low / HighN/A - N/A
Volume1.0 M
  • Latest Stories
  • Commentary and Analysis
Research Alert: CFRA Cuts View On Biomarin Pharmaceutical Inc. To Buy From Strong Buy
2:30PM ET 10/22/2021 MT Newswires

CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as...

Stifel Upgrades BioMarin Pharmaceutical to Buy from Hold, Adjusts Price Target to $96 from $86
7:37AM ET 9/09/2021 MT Newswires

BioMarin Pharmaceutical (BMRN) has an average rating of outperform and price targets ranging from $81 to $165, according to analysts polled by Capital IQ....

Sector Update: Health Care Stocks Falling This Afternoon
3:54PM ET 9/07/2021 MT Newswires

Health care stocks traded above their earlier lows this afternoon, with the NYSE Health Care Index falling 0.7% while the SPDR Health Care Select Sector...

Sector Update: Health Care
3:35PM ET 9/07/2021 MT Newswires

Health care stocks traded above their earlier lows this afternoon, with the NYSE Health Care Index falling 0.7% while the SPDR Health Care Select Sector...

Sector Update: Health Care Stocks Flat To Lower Pre-Bell Tuesday
9:15AM ET 9/07/2021 MT Newswires

Health care stocks were flat to lower pre-bell Tuesday. The iShares NASDAQ Biotechnology Index (IBB) was inactive while the Health Care SPDR (XLV) was down...

Sector Update: Health Care
8:56AM ET 9/07/2021 MT Newswires

Health care stocks were flat to lower pre-bell Tuesday. The iShares NASDAQ Biotechnology Index (IBB) was inactive while the Health Care SPDR (XLV) was down...

BioMarin Says FDA Orders Clinical Hold on Phase 1/2 Gene Therapy Trial in Phenylketonuria
4:16AM ET 9/07/2021 MT Newswires

BioMarin Pharmaceutical (BMRN) said Sunday that the US Food and Drug Administration has placed its phase 1/2 trial of BMN 307 gene therapy in adults with...

Wedbush Lifts Price Target on BioMarin Pharmaceutical to $152 From $141 After European Vosoritide Approval; Outperform Rating Kept
6:25AM ET 8/30/2021 MT Newswires

BioMarin Pharmaceutical (BMRN) has an average rating of outperform and price targets ranging from $81 to $165, according to analysts polled by Capital IQ....

BioMarin Pharmaceutical Receives European Commission Marketing Authorization for Voxzogo
9:27AM ET 8/27/2021 MT Newswires

BioMarin Pharmaceutical (BMRN) said the European Commission has granted marketing authorization for Voxzogo to treat achondroplasia in children. The...

Insider Trends: 90-Days of Insider Buying at BioMarin Pharmaceuticals Eased Back with Share Disposition
5:02PM ET 8/04/2021 MT Newswires

George Eric Davis, EVP, General Counsel, reported a sale of 5,518 shares in BioMarin Pharmaceuticals (BMRN) on Aug 02, 2021, for $423,175. Davis,...